Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib*-Reference-Cited by-同舟云学术

Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib*

Published:2006-07 Issue:2 Volume:134 Page:145-156
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Shringarpure Reshma,Catley Laurence,Bhole Deepak,Burger Renate,Podar Klaus,Tai Yu-Tzu,Kessler Benedikt,Galardy Paul,Ploegh Hidde,Tassone Pierfrancesco,Hideshima Teru,Mitsiades Constantine,Munshi Nikhil C.,Chauhan Dharminder,Anderson Kenneth C.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2006.06132.x/fullpdf

Reference53 articles.

1. Development of the Proteasome Inhibitor PS-341

2. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

3. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center;BMC Cancer;2023-05-31

2. HSP90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center;2022-11-08

3. Bortezomib Inhibits Multiple Myeloma Cells by Transactivating ATF3 to Trigger miR-135a-5p- Dependent Apoptosis;Frontiers in Oncology;2021-09-22

4. Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line;Medical Oncology;2021-08-07

5. Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma;Resistance to Targeted Anti-Cancer Therapeutics;2021